东亚药业就募集资金使用问题发布整改报告 拟调整研发中心建设项目用途

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. has released a rectification report addressing issues related to the use of raised funds, as highlighted by the Zhejiang Securities Regulatory Bureau [1][2][3] Group 1: Rectification Measures - The company plans to adjust the use of raised funds, improve review procedures, and enhance information disclosure to strengthen internal control governance [1][2] - The adjustment includes converting the construction project of the R&D center into a comprehensive administrative building, while maintaining the existing R&D area [2] - The company has organized specialized training for its board members and management to enhance compliance awareness and information disclosure management [2] Group 2: Compliance and Governance - The rectification aims to improve the company's internal control governance, ensuring compliance and promoting sustainable development [3] - The announcement did not indicate any significant impact on the company's daily operations due to these issues [3]